Compare Salesforce Inc (CRM) vs Regeneron Pharmaceuticals Inc (REGN) Price & Performance

Salesforce (CRM) trades at $227.80, up 1.25% with a bearish technical signal despite strong fundamentals. The company reported robust earnings beats in recent quarters with Q2 2026 EPS of $5.90 versus $3.27 expected. Revenue grew to $37.90B in 2025 with impressive 77.28% gross margins and 21.99% net income margin. Analyst consensus remains strongly bullish with 76.5% buy ratings and $271.91 price target, representing 19% upside potential.

The stock presents a compelling value opportunity with reasonable P/E of 20.56 and strong profitability metrics, though technical indicators signal near-term weakness. Key risks include AI-driven software sector volatility and macroeconomic headwinds affecting enterprise spending. Current levels offer attractive entry for long-term investors given the company's dominant market position and consistent execution.

Regeneron Pharmaceuticals (REGN) trades at $739.57, up 0.12% on the day, with a bearish technical signal but strong fundamental performance. Recent earnings have consistently beaten estimates, and the company maintains robust profitability with a net income margin of 27.86%. A major $8 billion expansion of the immunology alliance with Sanofi, announced October 1, 2026, provides significant future revenue potential and strategic momentum.

The outlook is positive, supported by strong earnings, a lucrative partnership, and a consensus analyst price target of $846. Key risks include competitive pressures in key drug markets and reliance on successful clinical trial outcomes. The stock presents a compelling opportunity for growth investors, though volatility may persist near-term.